drugset / Trial / NCT04226456

Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity

NCT04226456

Phase 4 Terminated 19 enrolled Centre Hospitalier Universitaire Saint Pierre
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the efficacity of N-acetylcystein against Cisplatin-induced ototoxicity.

Timeline

Start
2021-07-10
Primary completion
2023-05-03
Completion
2023-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 0.4 ml Other
Subject N-acetylcysteine Small molecule 1 ml Other
Subject N-acetylcysteine Small molecule 10 % Other